---
layout: minimal-medicine
title: Ajmaline
---

# Ajmaline
### Generic Name
Ajmaline

### Usage
Ajmaline is a class IA antiarrhythmic drug primarily used to treat life-threatening ventricular and supraventricular arrhythmias.  Its primary use is in managing acute, emergency situations involving these irregular heartbeats.  Specific arrhythmias it's used for include AV junctional tachycardia, supraventricular tachycardia (particularly in patients with Wolff-Parkinson-White syndrome), and paroxysmal atrial fibrillation.  It's important to note that Ajmaline is usually reserved for situations where other treatments have failed or aren't suitable.  Off-label, it's sometimes used as a diagnostic aid in identifying Brugada syndrome.

### Dosage
**Adult Dosage:** Ajmaline dosage is highly individualized and requires careful monitoring.  Administration should always be in a setting with continuous ECG monitoring and resuscitation capabilities readily available.  Dosage adjustments are crucial if the QRS interval increases by more than 25%, the PQ interval increases by more than 50%, the QT interval increases by 25% or exceeds 500 milliseconds, or if the patient experiences worsening or increased arrhythmias.

* **Acute/Emergency Injection (IV):**  Administered at a rate of 10 mg/minute, with a maximum single dose of 50 mg.  The injection is stopped once the arrhythmia is controlled.  A repeat dose may be given after 30 minutes if necessary. In patients with pre-existing heart damage, the injection should be slower (e.g., 50 mg over 15-20 minutes).

* **Prolonged Infusion (IV) for Refractory Tachycardic Ventricular Arrhythmias:**  An initial infusion rate of 20 mg/hour is used, potentially increasing to 50 mg/hour as needed.  The maximum cumulative daily dose is 1.2 grams.  Lower doses (10-30 mg/hour) are typically sufficient for patients with decompensated heart failure due to reduced drug clearance.

* **Diagnostic Aid for Brugada Syndrome (Off-Label):**  1 mg/kg administered intravenously over 5-10 minutes.

**Pediatric Dosage:** The safety and efficacy of Ajmaline in children have not been established.

**Dosage Adjustments:**

* **Hepatic Impairment:**  For single-dose injections, specific dosage adjustments aren't provided in the manufacturer's labeling, but caution is advised. For prolonged infusions, reduce the dose to 10-30 mg/hour due to reduced clearance.
* **Renal Impairment:** No dosage adjustment is typically needed.

### Side Effects
**Common Side Effects:** The frequency of side effects is not consistently defined in available literature.

**Less Common but Serious Side Effects:**

* Agranulocytosis (severe decrease in white blood cells)
* Bone marrow depression
* Hemolysis (destruction of red blood cells)
* Thrombocytopenia (low platelet count)
* Hepatitis
* Glomerulonephritis (kidney inflammation)
* Renal failure
* Severe hypotension (low blood pressure)
* Exacerbation of cardiac arrhythmias
* Worsening of heart failure

**Other reported side effects (frequency not specified):** Erythema (redness), skin rash, hot flashes, cholestasis (bile duct blockage), eosinophilia (increased eosinophils), antibody development, arthralgia (joint pain), blepharospasm (eyelid spasm), anorexia (loss of appetite), asystole (absence of heartbeat), atrioventricular block, constipation, convulsions (after rapid IV infusion), diarrhea, increased serum transaminase levels, intrahepatic cholestasis, nausea, paresthesia (after rapid IV infusion), sinoatrial block, sinus bradycardia, ventricular dysfunction, ventricular tachycardia, vomiting.

**Important Note:**  Any adverse effects should be reported to a healthcare provider immediately.


### How it Works
Ajmaline is a sodium channel blocker.  It works by decreasing the excitability and conduction velocity of the heart muscle, potentially depressing contractility (the force of heart muscle contractions).  This action lengthens the duration of the action potential and the refractory period in the atrial and ventricular muscles, preventing the generation of spontaneous, irregular heartbeats.


### Precautions
**Contraindications:** Ajmaline is contraindicated in patients with:

* Hypersensitivity to Ajmaline or any formulation components.
* Complete heart block.
* Second-degree atrioventricular (AV) block.
* Pre-existing conduction abnormalities in the ventricles.
* Adams-Stokes seizures (a type of seizure caused by heart rhythm problems).
* Heart failure (with an ejection fraction <35%).
* Myasthenia gravis (a neuromuscular disorder).
* Hypertrophic cardiomyopathy (a heart muscle disorder).
* Bradycardia (<50 bpm).
* Tachycardia caused by heart failure.
* Within 3 months of a myocardial infarction (heart attack).
* Prolonged QT interval or widening of the QRS interval.
* Cardiac glycoside poisoning.

**Warnings and Precautions:** Use with caution in patients with:

* First-degree AV block.
* Sick sinus syndrome.
* Incomplete bundle-branch block.
* Heart failure.
* Hepatic impairment or reduced hepatic blood flow.
* Hypotension (low blood pressure).
* Renal impairment.

**Drug Interactions:** Ajmaline interacts with numerous medications, including other antiarrhythmics, certain antibiotics, antidepressants, antipsychotics, and other drugs that can prolong the QT interval or cause bradycardia.  The interaction profiles are extensive and require careful evaluation by a healthcare professional.  This section has been heavily condensed to avoid excessive repetition; a comprehensive list can be found in the provided details.  Always inform your healthcare provider of all medications you are taking.


**Pregnancy and Lactation:** The safety of Ajmaline during pregnancy is unknown. Other medications are usually preferred for treating acute arrhythmias in pregnant women, but Ajmaline might be used if necessary.  Avoid use during the first trimester. Excretion in breast milk is also unknown.


### FAQs
* **Q: How should I store Ajmaline?** A:  Store Ajmaline as directed by your pharmacist or healthcare provider.  Generally, this involves keeping it in a cool, dry place, away from direct sunlight and moisture.

* **Q: Can I drive or operate machinery after taking Ajmaline?** A: Ajmaline can cause dizziness or other CNS effects. Avoid activities requiring alertness until you know how the medication affects you.

* **Q: What should I do if I miss a dose?** A:  Ajmaline is typically administered in a hospital setting for acute situations; missed doses aren't usually relevant in this context.  Always consult your healthcare provider.

* **Q: How long does Ajmaline take to work?** A: The onset of effect depends on the route of administration and individual factors. The effects of intravenous Ajmaline are generally rapid.

* **Q: What are the long-term effects of Ajmaline?** A:  Ajmaline is usually used for acute treatment, not long-term management.  Potential long-term effects are not comprehensively studied.  Discuss any concerns with your healthcare provider.

**Disclaimer:** This information is intended for educational purposes only and should not be considered medical advice. Always consult with a healthcare professional before starting or changing any medication, including Ajmaline.  The detailed drug interaction information provided in the original data is highly complex and requires professional interpretation.
